Can Axillary Dissection be Avoided by Improved Molecular Biological Diagnosis?

References

• Graversen H, Blichert-Toft M, Andersen J, Zedeler K. Breast cancer: risk of axillary recurrence in node-negative patients following partial dissection of the axilla. Eur J Surg Oncol 1988; 14: 407–12.
   PubMedGoogle Scholar
• Ivens D, Hoe AL, Podd TJ, Hamilton CR, Taylor I, Royle GT. Assessment of morbidity from complete axillary dissec-tion. Br J Cancer 1992; 66: 136–8.
   PubMed Web of Science ®Google Scholar
• Swedborg I, Wallgren A. The effect of pre- and postmastec-tomy radiotherapy on the degree of edema, shoulder-joint mobility, and gripping force. Cancer 1981; 47: 877–81.
   PubMed Web of Science ®Google Scholar
• Swedborg I, Borg G, Sarnelid M. Somatic sensation and discomfort in the arm of post-mastectomy patients. Scand J Rehabil Med 1981; 13: 23–9.
   Google Scholar
• Maunsell E, Brisson J, Deschenes L. Arm problems and psychological distress after surgery for breast cancer. Can J Surg 1993; 36: 315–20.
   Google Scholar
• Hladiuk M, Huchcroft S, Temple W, Schnurr BE. Arm function after axillary dissection for breast cancer: a pilot study to provide parameter estimates. J Surg Oncol 1992; 50: 47–52.
   PubMed Web of Science ®Google Scholar
• Marks L, Halperin E, Prosnitz L, et al. Post-mastectomy radiotherapy following adjuvant chemotherapy and au-tologous bone marrow transplantation for breast cancer pa-tients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B. Int .1- Radiat Oncol Biol Phys 1992; 23: 1021–6.
   PubMed Web of Science ®Google Scholar
• Bergh J, Wiklund T, Erikstein B, et al. Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity to high-risk breast can-cer patients. Ann Oncol 1998; 9: 403–11.
   PubMed Web of Science ®Google Scholar
• Fisher B, Brown A, Mamounas E, et al. Effect of preopera-tive chemotherapy on local-regional disease in women with operable breast cancer: findings from NSABP B-18. J Clin Oncol 1997; 15: 2483–93.
   PubMed Web of Science ®Google Scholar
• Mauriac L, Durand M, Avril A, Dilhuydy J-M. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Re-sults of a randomized trial in a single centre. Ann Oncol 1991; 2: 347–54.
   Google Scholar
• Scholl S, Fourguet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tu-mours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994; 30A: 645–52.
   PubMed Web of Science ®Google Scholar
• Powles T, Hickish T, Markris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995; 13: 547–52.
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Glick JH, Gelber RD, Senn HJ. International consensus panel on the treatment of primary breast cancer V: update 1998. Recent Results Cancer Res 1998; 152: 481–97.
   PubMedGoogle Scholar
• Morrow M. Axillary dissection: When and how radical? Semin Surg Oncol 1996; 12: 321–7.
   PubMedGoogle Scholar
• Ahlgren J, Stal 0, Westman G, Amesson LG. Prediction of axillary lymph node metastases in a screened breast cancer population. South-East Sweden Breast Cancer Group. Acta Oncol 1994; 33: 603–8.
   Google Scholar
• Ravdin PM, De Laurentiis M, Vendely T, Clark GM. Predic-tion of axillary lymph node status in breast cancer patients by use of prognostic indicators. J Natl Cancer Inst 1994; 86: 1771–5.
   PubMedGoogle Scholar
• Harris J, Morrow M. Treatment of early-stage breast cancer. In: Harris J, Lippman M, Morrow M, Hellman S, eds. Diseases of the breast. Philadelphia: Lippincott-Raven Pub-lishers, 1996: 487–547.
   Google Scholar
• Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997; 349: 1864–7.
   PubMed Web of Science ®Google Scholar
• Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220: 391–8, discussion 8-401.
   PubMed Web of Science ®Google Scholar
• Steeg PS, Bevilacqua G, Kopper L, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988; 80: 200–4.
   PubMed Web of Science ®Google Scholar
• Leone A, Flatow U, King CR, et al. Reduced tumor inci-dence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell 1991; 65: 25–35.
   PubMed Web of Science ®Google Scholar
• Leone A, Flatow U, VanHoutte K, Steeg PS. Transfection of human nm23-H1 into the human MDA-MB-435 breast car-cinoma cell line: effects on tumor metastatic potential, colo-nization and enzymatic activity. Oncogene 1993; 8: 2325–33.
   PubMed Web of Science ®Google Scholar
• Gilles AM, Presecan E, Vonica A, Lascu I. Nucleoside diphosphate kinase from human erythrocytes. Structural characterization of the two polypeptide chains responsible for heterogeneity of the hexameric enzyme. J Biol Chem 1991; 266: 8784–9.
   Google Scholar
• Bevilacqua G, Sobel ME, Liotta LA, Steeg PS. Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Can-cer Res 1989; 49: 5185–90.
   PubMed Web of Science ®Google Scholar
• Sawan A, Lascu I, Veron M, et al. NDP-K/nm23 expression in human breast cancer in relation to relapse, survival, and other prognostic factors: an immunohistochemical study. J Pathol 1994; 172: 27–34.
   PubMed Web of Science ®Google Scholar
• Nakamori S, Ishikawa 0, Ohhigashi H, et al. Expression of nucleoside diphosphate kinase/nm23 gene product in human pancreatic cancer: an association with lymph node metastasis and tumor invasion. Clin Exp Metastasis 1993; 11: 151–8.
   Google Scholar
• Hailat N, Keim DR, Melhem RF, et al. High levels of p19/nm23 protein in neuroblastoma are associated with ad-vanced stage disease and with N-myc gene amplification. J Clin Invest 1991; 88: 341–5.
   PubMed Web of Science ®Google Scholar
• Haut M, Steeg PS, Willson JK, Markowitz SD. Induction of nm23 gene expression in human colonic neoplasms and equal expression in colon tumors of high and low metastatic poten-tial. J Natl Cancer Inst 1991; 83: 712–6.
   PubMed Web of Science ®Google Scholar
• Harris C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996; 88: 1442–55.
   PubMed Web of Science ®Google Scholar
• Lesoon-Wood LA, Kim WH, Kleinman HK, Weintraub BD, Mixson AJ. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther 1995; 6: 395–405.
   PubMed Web of Science ®Google Scholar
• Clayman GL, el-Naggar AK, Roth JA, et al. In vivo molecu-lar therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995; 55: 1–6.
   Google Scholar
• Norberg T, Lennerstrand J, Inganas M, Bergh J. Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors. Int J Cancer 1998; 79: 376–83.
   PubMed Web of Science ®Google Scholar
• Sjogren S, Ingands M, Norberg T, et al. The p53 gene in breast cancer: prognostic value of complementary DNA se-quencing versus immunohistochemistry. J Natl Cancer Inst 1996; 88: 173–82.
   PubMed Web of Science ®Google Scholar
• Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med 1995; 1: 1029–34.
   Google Scholar
• Roth J, Nguyen D, Lawrence D, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 1996; 2: 985–91.
   PubMed Web of Science ®Google Scholar
• Roth JA, Swisher SG, Merritt JA, et al. Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 gene replacement. Semin Oncol 1998; 25 (Suppl 8): 33–7.
   PubMedGoogle Scholar
• Beck W, Dalton W. Mechanisms of drug resistance. In: DeVita V, Hellman S, Rosenberg S, eds. Cancer: principles & practise of Oncology. 5th ed. Philadelphia, New York: Lip-pincott-Raven Publishers, 1997: 498–512.
   Google Scholar
• Aas T, Borresen A-L, Geisler S, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 1996; 2: 811–4.
   Google Scholar
• Clahsen P, van de Velde C, Duval C, et al. p53 protein accumulation and response to adjuvant chemotherapy in pre-menopausal women with node-negative early breast cancer. J Clin Oncol 1998; 16: 470–9.
   PubMedGoogle Scholar
• Larsson L, Carlsson G, Sjogren S, et al. Mutations in the p53 gene predict the clinical outcome of adjuvant therapy in node-positive patients with early breast cancer. In: 35th ASCO Annual Meeting; submitted to ASCO 1999; Atlanta, Georgia: submitted to ASCO 1999.
   Google Scholar
• Linn S, Pinedo H, van Ark-Otte J, et al. Expression of drug resistance proteins in breast cancer, in relation to chemother-apy. Int J Cancer 1997; 71: 787–95.
   Google Scholar
• Thor A, Berry D, Budman D, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998; 90: 1346–60.
   PubMed Web of Science ®Google Scholar
• Borresen-Dale A. Subgroups of p53 mutations may predict the clinical behaviour of cancers in the breast and colon and contribute to therapy response. In: Klijn J, ed. Prognostic and predictive value of p53. Amsterdam: Elsevier Science By, 1997: 23–33.
   Google Scholar
• Bergh J. Clinical studies of p53 in treatment and benefit of breast cancer patients. 1999 (in press).
   Google Scholar
• Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of throm-bospondin-1. Science 1994; 265: 1582–4.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular en-dothelial growth factor gene expression. Cancer Res 1995; 55: 6161–5.
   Google Scholar
• Linderholm B, Tavelin B, Grankvist K, Henriksson R. Vascu-lar endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 1998; 16: 3121–8.
   PubMed Web of Science ®Google Scholar
• Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indi-cator of node metastases and survival in breast cancer. Lancet 1992; 340: 1120–4.
   PubMed Web of Science ®Google Scholar
• Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84: 1875–87.
   PubMed Web of Science ®Google Scholar
• Toi M, Kashitani J, Tominaga T. Tumor angiogenesis is an independent prognostic indicator in primary breast car-cinoma. Int .1- Cancer 1993; 55: 371–4.
   Google Scholar
• Bosari S, Lee A, DeLellis R, Wiley B, Heatley G, Silverman M. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992; 23: 755–61.
   PubMed Web of Science ®Google Scholar
• Siitonen SM, Haapasalo HK, Rantala IS, HelM HJ, Isola JJ. Comparison of different immunohistochemical methods in the assessment of angiogenesis: lack of prognostic value in a group of 77 selected node-negative breast carcinomas. Mod Pathol 1995; 8: 745–52.
   Google Scholar
• Costello P, McCann A, Carney DN, Dervan PA. Prognostic significance of microvessel density in lymph node negative breast carcinoma. Hum Pathol 1995; 26: 1181–4.
   PubMed Web of Science ®Google Scholar
• Van Hoef ME, Knox WF, Dhesi SS, Howell A, Schor AM. Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer 1993; 8: 1141–5.
   Google Scholar
• Axelsson K, Ljung BM, Moore DH, II, et al. Tumor angio-genesis as a prognostic assay for invasive ductal breast car-cinoma. J Natl Cancer Inst 1995; 87: 997–1008.
   PubMed Web of Science ®Google Scholar
• Lindblom A, Linder S. The metastatic phenotype-prognos-tic implications. Crit Rev Oncol Hematol 1996; 24: 71–96.
   PubMedGoogle Scholar
• Oka H, Shiozaki H, Kobayashi K, et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 1993; 53: 1696–701.
   PubMed Web of Science ®Google Scholar
• Berx G, Nollet F, van Roy F. Dysregulation of the E-cad-herin/catenin complex by irreversible mutations in human carcinomas. Cell Adhes Commun 1998; 6: 171–84.
   Google Scholar
• Powell WC, Knox JD, Navre M, et al. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 1993; 53: 417–22.
   PubMed Web of Science ®Google Scholar
• Sreenath T, Matrisian LM, Stetler-Stevenson W, Gattoni-Celli S, Pozzatti RO. Expression of matrix metalloproteinase genes in transformed rat cell lines of high and low metastatic potential. Cancer Res 1992; 52: 4942–7.
   Google Scholar
• Tetu B, Brisson J, Lapointe H, Bernard P. Prognostic signifi-cance of stromelysin 3, gelatinase A, and urokinase expression in breast cancer. Hum Pathol 1998; 29: 979–85.
   PubMedGoogle Scholar
• Wolf C, Rouyer N, Lutz Y, et al. Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibrob-lastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci USA 1993; 90: 1843–7.
   PubMed Web of Science ®Google Scholar
• Engel G, Heselmeyer K, Auer G, Backdahl M, Eriksson E, Linder S. Correlation between stromelysin-3 mRNA level and outcome of human breast cancer. Int J Cancer 1994; 58: 830–5.
   PubMed Web of Science ®Google Scholar
• Duffy MJ. Proteases as prognostic markers in cancer. Clin Cancer Res 1996; 2: 613–8.
   PubMed Web of Science ®Google Scholar
• Clark G. Prognostic and predictive factors. Philadelphia, New York: Lippincott-Raven, 1996.
   Google Scholar
• Thorpe SM, Rochefort H, Garcia M, et al. Association between high concentrations of Mr 52 000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 1989; 49: 6008–14.
   PubMed Web of Science ®Google Scholar
• Stephens RW, Brunner N, Janicke F, Schmitt M. The uroki-nase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 1998; 52: 99–111.
   PubMed Web of Science ®Google Scholar
• Foekens JA, Schmitt M, van Putten WL, et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994; 12: 1648–58.
   PubMed Web of Science ®Google Scholar
• Bouchet C, Spyratos F, Martin PM, Hacene K, Gentile A, Oglobine J. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 1994; 69: 398–405.
   PubMed Web of Science ®Google Scholar
• Grondahl-Hansen J, Christensen IJ, Briand P, et al. Plasmi-nogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. Clin Cancer Res 1997; 3: 233–9.
   Google Scholar
• Hekman CM, Loskutoff DJ. Fibrinolytic pathways and the endothelium. Semin Thromb Hemostas 1987; 13: 514–27.
   PubMedGoogle Scholar
• Ellis V, Wun TC, Behrendt N, Ronne E, Dano K. Inhibition of receptor-bound urokinase by plasminogen-activator in-hibitors. J Biol Chem 1990; 265: 9904–8.
   Google Scholar
• Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated ser-pins. Mol Cell Endocrinol 1990; 68: 1–19.
   Google Scholar
• Reilly D, Christensen L, Duch M, Nolan N, Duffy MJ, Andreasen PA. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer 1992; 50: 208–14.
   PubMed Web of Science ®Google Scholar
• Pyke C, Kristensen P, Ralfkiaer E, Eriksen J, Dano K. The plasminogen activation system in human colon cancer: mes-senger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res 1991; 51: 4067–71.
   Google Scholar
• Montesano R, Pepper MS, Mohle-Steinlein U, Risau W, Wagner EF, Orci L. Increased proteolytic activity is responsi-ble for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 1990; 62: 435–45.
   Google Scholar
• Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232: 1644–6.
   Google Scholar
• Revillion F, Bonneterre J, Peyrat J. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998; 34: 791–808.
   PubMedGoogle Scholar
• Barbareschi M, Leonardi E, Mauri F, Serio G, Della Palma P. p53 and c-erbB-2 protein expression in breast carcinoma. Am J Clin Pathol 1992; 98: 408–18.
   PubMedGoogle Scholar
• Berns E, Klijn J, van Staveren I, Portengen H, Noordegraaf E, Foekens J. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer 1992; 28: 697–700.
   PubMedGoogle Scholar
• Carlomagno C, Perrone F, Gallo C, et al. c-erbB2 overexpres-sion decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996; 14: 2702–8.
   PubMed Web of Science ®Google Scholar
• Gusterson B, Gelber R, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992; 10: 1049–56.
   PubMed Web of Science ®Google Scholar
• Hartmann L, Ingle J, Wold L, et al. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment proto-col. Cancer 1994; 74: 2956–63.
   Google Scholar
• Ji H, Lipponen P, Aaltomaa S, Syrjdnen S, Syrjänen K. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer. Anticancer Res 1993; 13: 1147–52.
   Google Scholar
• Marx D, Schauer A, Reiche C, et al. c-erbB2 expression in correlation to other biological parameters of breast cancer. J Cancer Res Clin Oncol 1990; 116: 15–20.
   PubMed Web of Science ®Google Scholar
• Sjögren S, Ingands M, Lindgren A, Holmberg L, Bergh J. The prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998; 16: 462–9.
   Google Scholar
• Takahashi S, Narimatsu E, Asanuma H, et al. Immunohisto-chemical detection of estrogen receptor in invasive human breast cancer: correlation with heat shock proteins, pS2 and oncogene products. Oncology 1995; 52: 371–5.
   PubMedGoogle Scholar
• Tang R, Kacinski B, Validire P, et al. Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells? J Cell Biochem 1990; 44: 189–98.
   PubMed Web of Science ®Google Scholar
• Guerin M, Gabillot M, Mathieu MC, et al. Structure and expression of c-erbB-2 and EGF receptor genes in inflamma-tory and non-inflammatory breast cancer: prognostic signifi-cance. Int .1- Cancer 1989; 43: 201–8.
   PubMedGoogle Scholar
• Borg Á, Baldetorp B, Ferno M, Killander D, Olsson H, Sigurdsson H. ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene 1991; 6: 137–43.
   Google Scholar
• Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–82.
   PubMed Web of Science ®Google Scholar
• Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994; 73: 2359–65.
   Google Scholar
• Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989; 7: 1120–8.
   Google Scholar
• Benz C, Scott G, Sarup J, et al. Estrogen-dependent, tamox-ifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1993; 24: 85–95.
   Web of Science ®Google Scholar
• Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90: 1361–70.
   PubMed Web of Science ®Google Scholar
• Cobleigh M, Vogel C, Tripathy D, et al. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who re-lapsed following chemotherapy for metastatic breast cancer. In: Perry M, ed. Thirty-Fourth Annual Meeting, 1998, Los Angeles, CA. Am Soc Clin Oncol 1998: 97a, (abstract 376).
   Google Scholar
• Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2 /MBC) markedly increases anticancer activ-ity: a randomized, multinational controlled phase III trial. In: Perry M, ed. Thirty-Fourth Annual Meeting, 1998, Los Ange-les, CA. Am Soc Clin Oncol 1998: 98a, (abstract 377).
   Google Scholar